Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue microarrays

Journal of the National Cancer Institute

Volumn 91, Issue 20, 1999, Pages 1758-1764

  Bubendorf, Lukas ^a   Kolmer, Meelis ^a,e   Kononen, Juha ^a   Koivisto, Pasi ^f   Mousses, Spyro ^a   Chen, Yidong ^a   Mahlamäki, Eija ^f   Schraml, Peter ^f   Moch, Holger ^f   Willi, Niels ^f   Elkahloun, Abdel G ^b   Pretlow, Thomas G ^c   Gasser, Thomas C ^f   Mihatsch, Michael J ^f   Sauter, Guido ^f   Kallioniemi, Olli P ^a,d  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b Research Genetics Inc   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; HEAT SHOCK PROTEIN; SOMATOMEDIN BINDING PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER HORMONE THERAPY; CANCER RECURRENCE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; TREATMENT FAILURE; TUMOR XENOGRAFT;

EID: 0033589283     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.20.1758     Document Type: Article

References (46)

1. Wingo PA, Ries LA, Giovino GA, Miller DS, Rosenberg HM, Shopland DR, et al. Annual report to the nation on the status of cancer. 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 1999;91:675-90.
2. Konety BR, Getzenberg RH. Novel therapies for advanced prostate cancer. Semin Urol Oncol 1997;15:33-42.
3. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57:406-12.
4. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56:3042-6.
5. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996;14:457-60.
6. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science 1995;270:484-7.
7. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844-7.
8. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM, et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994;54:6049-52.
9. Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI, et al. Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst 1993;85:394-8.
10. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 1998;21:177-84.
11. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979;18:5294-9.
12. Gleason DF. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology: the prostate. Philadelphia (PA): Lea & Febiger; 1977. p. 171-8.
13. International Union Against Cancer. Classification of malignant tumours. 5th ed. New York (NY): Wiley-Liss; 1997.
14. Schraml P, Kononen J, Bubendorf L, Moch H. Bissig H, Nocito A, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999;5: 1966-75.
15. Lee AV, Hilsenbeck SG, Yee D. IGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat 1998;47: 295-302.
16. Nunn SE, Gibson TB, Rajah R, Cohen P. Regulation of prostate cell growth by the insulin-like growth factor binding proteins and their proteases. Endocrine 1997;7:115-8.
17. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
18. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351:1393-6.
19. Burfeind P, Chernicky CL, Rininsland F, Ilan J, Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci U S A 1996;93:7263-8.
20. Baxter RC, Binoux MA, Clemmons DR, Conover CA, Drop SL, Holly JM, et al. Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily. Endocrinology 1998;139:4036.
21. Harrington EA, Bennett MR, Fanidi A, Evan GI. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 1994; 13:3286-95.
22. Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991;73:401-7.
23. Cohen P, Peehl DM, Baker B, Liu F, Hintz RL, Rosenfeld RG. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 1994;79:1410-5.
24. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-betal on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997; 272:12181-8.
25. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-8.
26. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
27. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996;28:619-37.
28. Helle SI, Jonat W, Giurescu M, Ekse D, Holly JM, Lonning PE. Influence of treatment with onapristone on the IGF-system in breast cancer patients. J Steroid Biochem Mol Biol 1998;66: 159-63.
29. el Atiq F, Garrouste F, Remacle-Bonnet M, Sastre B, Pommier G. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 1994;57: 491-7.
30. Kanety H, Kattan M, Goldberg I, Kopolovic J, Ravia J, Menczer J, et al. Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. Br J Cancer 1996;73:1069-73.
31. Reeve JG, Morgan J, Schwander J, Bleehen NM. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Cancer Res 1993;53:4680-5.
32. Menouny M, Binoux M, Babajko S. IGFBP-2 expression in a human cell line is associated with increased IGFBP-3 proteolysis, decreased IGFBP-1 expression and increased tumorigenicity. Int J Cancer 1998;77:874-9.
33. Samali A, Cotter TG. Heat shock proteins increase resistance to apoptosis. Exp Cell Res 1996;223:163-70.
34. Mehlen P, Mickey E, Weber LA, Arrigo AP. Large unphosphorylated aggregates as the active form of hsp27 which controls intracellular reactive oxygen species and glutathione levels and generates a protection against TNFalpha in NIH-3T3-ras cells. Biochem Biophys Res Commun 1997;241:187-92.
35. Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SA. The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 1993;53:4443-8.
36. Huot J, Houle F, Spitz DR, Landry J. HSP27 phosphorylation-mediated resistance against actin fragmentation and cell death induced by oxidative stress. Cancer Res 1996;56:273-9.
37. Koivisto P, Visakorpi T, Rantala I, Isola J. Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. J Pathol 1997;183:51-6.
38. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
39. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55: 4438-45.
40. Guenal I, Sidoti-de Fraisse C, Gaumer S, Mignotte B. Bcl-2 and Hsp27 act at different levels to suppress programmed cell death. Oncogene 1997;15:347-60.
41. Love S, King RJ. A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br J Cancer 1994; 69:743-8.
42. Conroy SE, Sasieni PD, Amin V, Wang DY, Smith P, Fentiman IS, et al. Antibodies to heat-shock protein 27 are associated with improved survival in patients with breast cancer. Br J Cancer 1998;77:1875-9.
43. Vargas-Roig LM, Fanelli MA, Lopez LA, Gago FE, Tello O, Aznar JC, et al. Heat shock proteins and cell proliferation in human breast cancer biopsy samples. Cancer Detect Prev 1997;21:441-51.
44. Vargas-Roig LM, Gago FE, Tello O, Aznar JC, Ciocca DR. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1998;79:468-75.
45. Thomas SA, Brown IL, Hollins GW, Hocken A, Kirk D, King RJ, et al. Detection and distribution of heat shock proteins 27 and 90 in human benign and malignant prostatic tissue. Br J Urol 1996;77:367-72.
46. Storm FK, Mahvi DM, Gilchrist KW. Hsp-27 has no diagnostic or prognostic significance in prostate or bladder cancers. Urology 1993;42: 379-82.